Caplin Point shares fall 13.23% after facility classified as “Official Action Indicated”
Key Facts
Caplin Point shares fell 13.23% from Friday’s close over 3 trading sessions through the November 18 report, after the U.S. Food and Drug Administration classified its inspection of the company’s Caplin Steriles facility in Gummidipoondi as “Official Action Indicated.” At 11:46 a.m. that day, the stock was down 7.2% at 2,085 rupees on the National Stock Exchange of India, according to a Business Standard report. The stock fell as much as 7.7% during the session, reaching a low of 2,072 rupees. The report said the classification concerns the company’s manufacturing facility for injectable formulations and eye drops. The shares’ losses came as the Nifty 50 was down 0.60% at 25,439.15 points in trading, according to the reading cited in the report at 11:46 a.m.
Caplin Point said in a filing with the stock exchanges that the unannounced inspection of the facility took place between August 13 and 21, 2026, and concluded with 10 observations that it described as procedural in nature. The company added that it received the FDA notification on November 16 and disclosed the classification to the exchanges on November 17. According to the FDA’s definition, the classification indicates that the facility is in an unacceptable state of compliance. The regulator says a facility classified in this category may have received an FDA-483 or FDA-4056 inspection observations form. This definition sets out the meaning of the regulatory classification, while the company’s filing does not announce any impact on exports to the United States.
Facing pressure on its shares, Caplin Point said it does not expect, as of the date of its filing, any material impact on its financial position or operations because of the classification. It said the facility continues to manufacture and supply products, keeping production and supply ongoing, according to the company’s statement. The filing did not identify any realized financial impact from the classification, nor did it say that supply had stopped. This concerns a facility associated with injectable products and eye drops, the activities covered by the inspection, according to the company. This leaves a gap between the stock’s decline over the sessions and the company’s assurance that the plant remains operational, without resolving the course of the regulatory response.
The FDA said the final inspection classification is usually sent to companies within 45 to 90 days of the inspection’s close, depending on its type. The inspection of the Gummidipoondi facility was closed on August 21, before the company said it received the notification on November 16. Caplin Point said it will work closely with the FDA to address the observations. It added that it will seek to demonstrate the effectiveness and sustainability of its corrective and preventive actions. The filing did not specify a deadline for completing this work or announcing a subsequent development on the classification.
In an update on its second-quarter fiscal 2027 results, the company had announced that first-half revenue exceeded 1,300 crore rupees and earnings before interest, taxes, depreciation and amortization exceeded 500 crore rupees, with each rising nearly 20% year over year. It also said average daily sales at its U.S. Caplin Steriles unit had increased from 32,936 dollars in fiscal 2026 to 61,330 dollars per day at the time of the update. The company said then that it expected to double revenue and earnings compared with fiscal 2026. In the same update, it reported that more than 5,600 U.S. customers had purchased products from the unit during its second full year of operations, up 20% from fiscal 2026. It also said the KOL-2 facility was expected to be completed by August 2027, with 5 lines for injectables and eye drops and vial-filling technology, and capacity to add 3 more lines. Addressing the inspection observations remains the next development the company has committed to pursue with the regulator.